O. O. Lyulko

RESTORE-IMI 1: A Multicenter, Randomized, Double-blind Trial Comparing Efficacy and Safety of Imipenem/Relebactam vs Colistin Plus Imipenem in Patients With Imipenem-nonsusceptible Bacterial Infections

J. Motsch, Cláudia Murta de Oliveira, V.P. Stus et al. · Clinical Infectious Diseases · 2019 · 404 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +17

Randomized, Double-Blind, Placebo-Controlled Phase III Study of Tasquinimod in Men With Metastatic Castration-Resistant Prostate Cancer

Cora N. Sternberg, Andrew J. Armstrong, Siobhan Ng et al. · Journal of Clinical Oncology · 2016 · 101 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

O4 Tivozanib hydrochloride versus sorafenib as initial targeted therapy for patients with advanced renal cell carcinoma: Results from the Phase III randomized, open-label, multicenter TIVO-1 trial

Robert J. Motzer, D. Nosov, Tim Eisen et al. · European Urology Supplements · 2012 · 19 citations

Medicine, Oncology, Pharmacology +7

Final analysis of the phase II randomized discontinuation trial (RDT) of tivozanib (AV-951) versus placebo in patients with renal cell carcinoma (RCC).

D. Nosov, Pankaj Bhargava, W. B. Esteves et al. · Journal of Clinical Oncology · 2011 · 19 citations

Medicine, Oncology, Pharmacotherapy +17

4BA A phase 3, randomized, double-blind, placebo-controlled study of tasquinimod (TASQ) in men with metastatic castrate resistant prostate cancer (mCRPC)

Michael A. Carducci, Anne Armstrong, Siew C. Ng et al. · European Journal of Cancer · 2015 · 10 citations

Medicine, Oncology, Urology +9